Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT05382052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
Lead sponsor
Fundación GECP
Phase
Observational
Overall status
Active, not recruiting
Start date
June 17, 2022
Completion date
December 30, 2027
Enrollment
100 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant treatment, non small cell lung cancer stage iii